1257 Hay Street
West Perth, WA 6005
Australia
61 8 6478 7816
https://www.artrya.com
Settore/i: Healthcare
Settore: Health Information Services
Impiegati a tempo pieno:
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. Mathew Regan | Chief Executive Officer | 460,49k | N/D | N/D |
Mr. John Konstantopoulos B.E. | Co-Founder and Executive of Commercial & Strategy | 287,46k | N/D | N/D |
Mr. Mark Wainwright | Chief Financial Officer | N/D | N/D | N/D |
Prof. Girish Dwivedi M.D. | Chief Scientific Officer | N/D | N/D | N/D |
Mr. Ted Schwab | Co-CEO of Artrya USA Inc | N/D | N/D | N/D |
Mr. Kevin Ronald Hart B.Com., B.Comm (Hons), C.A., F.C.A. | Company Secretary | N/D | N/D | 1962 |
Artrya Limited operates as a medical technology company that uses artificial intelligence (AI) to identify patients at risk of coronary artery disease. It offers Salix, a cloud-based software that uses its AI to automate the detection of coronary artery disease from coronary computed tomography angiography. Artrya Limited was incorporated in 2018 and is based in West Perth, Australia.
L'ISS Governance QualityScore di Artrya Limited al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.